HYPOGLYCEMIA PREVENTION AFTER EXERCISE IN ADOLESCENT T1DM

青少年 T1DM 运动后低血糖的预防

• 批准号: 8167207
• 负责人: MARC D BRETON
• 金额: $ 0.27万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-01 至 2013-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167207
• 关键词: Adolescent; Artificial Pancreas; Computer Retrieval of Information on Scientific Projects Database; Environment; Event; Exercise; Frequencies; Funding; Glucose; Grant; Health; Hospitals; Hyperglycemia; Hypoglycemia; Injection of therapeutic agent; Institution; Insulin; Insulin-Dependent Diabetes Mellitus; Metabolic; Monitor; Patient Monitoring; Patients; Performance; Prevention; Protocols documentation; Regulation; Research; Research Personnel; Resources; Sleep; Source; System; Testing; Time; Toxic effect; United States National Institutes of Health; Variant; base; blood glucose regulation; design; prevent; subcutaneous

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. As artificial pancreas systems are tested in hospital settings and eventually in field conditions, it becomes apparent that such systems suffer from ample glucose excursions, both in hypoglycemia and hyperglycemia. The need for supervisory systems that prevent such large glucose variation rise from the incapacity of modern controllers to properly adapt and react to very high and/or very low glucose, and the resulting qualitative metabolic changes (e.g. counter-regulation and gluco-toxicity). Such supervisory systems, called controllers to range, are not aiming at perfect glucose control (i.e. glucose variations comparable to health) but at mitigating large glucose deviations, keeping the patient safe and create the environment for more precise control strategies to function optimally. This protocol is designed to demonstrate the feasibility in a GCRC setting of such a supervisory system during different metabolic conditions, such as meals, mild exercise and sleep. Our system is based on continuous monitoring and subcutaneous insulin injections, and monitors the patient's regular treatment, i.e. unless an error in treatment is detected (glucose going low or high) the system will stay inactive. Performances of the system will be assessed using frequency of hypoglycemic events and amount of time spent in a wide glucose target range.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此，可以在其他清晰的条目中表示。列出的机构是 对于中心，这不一定是调查员的机构。 由于人工胰腺系统在医院环境中进行了测试，并最终在现场条件下进行了测试，因此很明显，这种系统在低血糖和高血糖中都遭受了充足的葡萄糖偏移。对预防这种大葡萄糖变化的监督系统的需求从现代控制器的丧失能力中升高，以适当适应并反应非常高和/或非常低的葡萄糖，以及由此产生的定性代谢变化（例如，反调节和葡萄糖毒性）。这样的监督系统，称为控制器的范围，不是针对完美的葡萄糖控制（即葡萄糖变化与健康相当），而是针对缓解巨大的葡萄糖偏差，确保患者的安全并为更精确的控制策略创造了最佳功能的环境。该方案旨在证明在不同代谢条件（例如餐，轻度运动和睡眠）的GCRC环境中的可行性。我们的系统基于连续监测和皮下胰岛素注射，并监视患者的常规治疗，即，除非检测到治疗错误（葡萄糖变低或高），该系统将保持不活跃。系统的性能将使用降血糖事件的频率以及在宽葡萄糖目标范围内花费的时间进行评估。